RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
Regen BioPharma Inc
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$0.00+0.00 (+50.00%)
Close on Oct 19, 2026
- Market cap
- $92.33K
- P/E (TTM)
- –
- Dividend yield
- –
Regen BioPharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Market Cap | $251.29K | $166.30M |
| Enterprise Value | $251.05K | $88.19M |
| PS Ratio | 1.06 | 3.65 |
Enterprise value
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| EV / Sales | 1.06 | 2.51 |
Income (trailing twelve months)
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Revenue | $236.56K | $58.34M |
| Operating Income | -$803.86K | -$21.40M |
| Pretax Income | -$1.19M | -$14.34M |
| Net Income | -$1.19M | -$22.46M |
| EBITDA | -$803.86K | -$16.91M |
Margins
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Operating Margin | -339.8% | -44.0% |
| Pretax Margin | -501.4% | -13.3% |
| Profit Margin | -501.4% | -40.2% |
| EBITDA Margin | -339.8% | -30.2% |
Returns
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Return on Assets (ROA) | -489.7% | -40.9% |
Growth
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 0.00% | 5.96% |
| Revenue Growth (3Y CAGR) | 23.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 16.5% | 6.48% |
Balance sheet
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $239 | $61.43M |
| Net Cash (Debt) | $239 | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | -$5.88M | $49.09M |
| Book Value Per Share | -$0.00 | $1.37 |
| Tangible Book Value | -$5.88M | $23.52M |
| Working Capital | -$5.88M | $76.81M |
Financial position
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Current Ratio | 0.05 | 3.34 |
| Quick Ratio | 0.05 | 2.44 |
| Interest Coverage | -4.72 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$445.25K | -$12.35M |
Efficiency
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Asset Turnover | 0.98 | 0.39 |
| Revenue Per Employee | $236.56K | $404.87K |
| Profits Per Employee | -$1.19M | -$703.34K |
| Employee Count | 1 | 74 |
Dividends and yields
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Earnings Yield | -472.0% | -23.3% |
Shares
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Shares Outstanding | 1,675,280,000 | 58,127,000 |
| Shares Change (YoY) | 1630.1% | 10.9% |
| Shares Change (QoQ) | 221.5% | 0.54% |
| Float | 1,675,280,000 | 49,136,700 |
| Shares Held by Insiders | 0.00% | 11.6% |
Taxes
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Regen BioPharma | Industry median |
|---|---|---|
| Altman Z-Score | -141.49 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Regen BioPharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.